Sagimet net loss widens to $14 million in Q2 FY26; R&D expense climbs to $11.54 million
SGMT•Cash balance boosted by April financing
Cash, cash equivalents and marketable securities rose to $257.56 million as of June 30, 2026, following a $175 million April equity financing.
CEO David Happel said the company is positioned to fund operations through 2028, including the Phase 3 readout and an NDA submission.
Denifanstat acne trial remains on track
The company said the denifanstat Phase 3 trial in moderate to severe acne remains on track to start in the second half of 2026.
Quarterly loss widens as R&D spending rises
Sagimet posted a net loss of $14 million for Q2 2026, widening from $10.39 million a year earlier.
Research and development expense climbed to $11.54 million, while general and administrative expense eased to $4.28 million.
